Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02781818 · ClinicalTrials.gov registry record · NA

A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.

A NA study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
32
Enrollment target

NCT02781818 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02781818, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
32 participants
Enrollment target

Study Summary

Purpose: To evaluate the effectiveness of intralesional triamcinolone for the treatment of hidradenitis suppurativa (HS) Participants: Patients diagnosed with Hidradenitis Suppurativa that have active inflammatory HS lesions. Up to 60 lesions will be treated. Between 20 and 60 patients will be enrolled dependent on the number of lesions they have treated. (up to 3 per patient) Procedures (methods): Injection of triamcinolone or placebo into active lesions of hidradenitis suppurativa

Interventions

  • DRUG Normal Saline
  • DRUG Triamcinolone Acetonide 40mg/mL
  • DRUG Triamcinolone Acetonide 10mg/mL

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2016-06
Est. Completion 2017-07
Phase NA

What the Registry Record Tells You About NCT02781818

The ClinicalTrials.gov registry entry for NCT02781818 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Normal Saline is the first listed.

NCT02781818 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02781818 about?

NCT02781818 is a clinical study titled "A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.". Purpose: To evaluate the effectiveness of intralesional triamcinolone for the treatment of hidradenitis suppurativa (HS) Participants: Patients diagnosed with Hidradenitis Suppurativa that have active inflammatory HS lesions. Up to 60 lesions will be treated. Between 20 and 60 patients will be enro...

What is the current status of trial NCT02781818?

This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2016-06. Estimated completion is 2017-07.

What interventions are being tested in trial NCT02781818?

The interventions under investigation include: Normal Saline (DRUG), Triamcinolone Acetonide 40mg/mL (DRUG), Triamcinolone Acetonide 10mg/mL (DRUG).

Who is sponsoring clinical trial NCT02781818?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.